-
Nature Sub-Journal: Reactivation of the "paralyzed" immune system to fatal brain cancer...
Time of Update: 2021-06-06
The study found that it was the cancer-promoting metabolite R-2-HG that interfered with the amino acid metabolism of "cell scavenger" macrophages, and activated the central immune system regulatory molecule aryl hydrocarbon receptor (AHR), thereby causing macrophages to produce Immunosuppressive response.
-
The first KRAS inhibitor has been accelerated approval for non-pharmacological targets to counter-attack a variety of drugs...
Time of Update: 2021-06-06
On May 28, 2021, the FDA announced the accelerated approval of the KRAS inhibitor Lumakras (sotorasib, AMG510) [1] for the treatment of non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations.
-
Subcutaneous injection of PD-L1 antibody Phase 1 clinical data published in the United States | The On...
Time of Update: 2021-06-06
On May 28th, a recombinant humanized PD-L1 single-domain antibody (Envolimab, KN035) strategically cooperated by Corning Jerry, Sidi Medicine and Simcere, was published in the internationally renowned medical journal The Oncologist Published full-text online data from a Phase 1 clinical trial in the United States.
-
The fourth batch of "Pharmaceutical Speed Reading Society" landed in Xinda PD-1 and the third indication will...
Time of Update: 2021-06-06
[May 31, 2021/Medical Information List] Johnson & Johnson's Erleada combined with ADT Therapy Phase 3 clinical trial has significant results; first-line squamous NSCLC!
According to the official website of NMPA, Yangzijiang Pharmaceutical's Class 1 new drug "Levoornidazole Phosphate Disodium for Injection" (acceptance number: CXHS1900022) has been approved for marketing.
-
U.S. FDA approval of listed drugs in the first quarter of 2021 and my country's domestic application status
Time of Update: 2021-06-06
Among the 30 NDA applications, there are Type 1 – 15 new molecular entities and new drugs, Type 2 – 1 new active ingredient classification, Type 3 – 4 new dosage forms, and Type 4 – 3 new compound drugs, Type 5-9 new preparations or new manufacturers of new drugs, of which CABENUVA KIT and AZSTARYS are both new molecular entities and new compounds.
-
KRAS inhibitor!
Time of Update: 2021-06-06
According to the press release, Jacos Pharmaceuticals will start multi-center clinical trials for tumor patients with non-small cell lung cancer, colorectal cancer and other solid tumors in China and the United States, and plan to start patient enrollment in the second half of 2021.
-
The real data tells you: How does the centralized drug compare to the original research drug?
Time of Update: 2021-06-06
Text | Yang Zi
Since 2018, the National Medical Insurance Administration has successively launched four batches of national drug centralized procurement, involving a total of 157 varieties and 533 s
-
Zejing Pharmaceutical's Class 1 new drug ``Donafinil Tosylate Tablets'' will soon be approved for advanced liver disease...
Time of Update: 2021-06-06
This new drug marketing application is mainly based on the results of an open, randomized, parallel controlled, multi-center phase II/III clinical study of Donafenib tosylate tablets for the first-line treatment of advanced hepatocellular carcinoma (trial code ZGDH3).
-
2021EHA/ASCO/ICML|Otuzumab-based program opens up new ideas for lymphoma treatment
Time of Update: 2021-06-05
New method: rapid infusion of otuzumab, safe and tolerable [ASCO-7545/EHA-EP807] GAZELLE study: the 2nd cycle and afterwards give FL patients rapid infusion of otuzumab, safe and feasible GAZELLE study is A prospective, open-label, multi-center, single-group, phase IV clinical study, which included 113 newly-treated FL patients, and there was no infusion-related level ≥3 after the first cycle (C1, standard infusion rate) treatment Response (IRR) patients receive Otuzumab (Obi) 90-minute rapid infusion (SDI) from C2.
-
Zhejiang University Shen Huahao/Ying Songmin team's Science publication reveals that eosinophils promote tumor metastasis
Time of Update: 2021-06-05
Recently, the Zhejiang Provincial Key Laboratory of Respiratory Disease Diagnosis, Treatment and Research, the Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital of Zhejiang University School of Medicine, Professor Shen Huahao and Professor Ying Songmin’s team discovered that eosinophils play a behind-the-scenes role in tumor metastasis.
-
Prof. Lu Liqin: Whole-process management of EGFR mutation-positive NSCLC
Time of Update: 2021-06-05
Professor Lu Liqin: CSCO guidelines recommend that TKI drugs are the first choice for the treatment of EGFR mutation-positive NSCLC, including first-generation, second-generation and third-generation TKI drugs.
-
Professor Ma Fei: Regarding the latest treatment progress in the field of breast cancer, you need to know this!
Time of Update: 2021-06-05
With these issues that the public and patients are most concerned about, the medical community has a dialogue with the authoritative expert-Professor Ma Fei, Director of the Internal Medicine Treatment Center of the National Cancer Center/Tumor Hospital of the Chinese Academy of Medical Sciences, and asked him to share his views on the diagnosis and treatment of breast cancer, and promote the public to this An understanding of malignant diseases.
-
Early use to reverse the decline: the first-line treatment for prostate cancer is not effective, and the addition of disulumab can quickly relieve bone pain and achieve long-term benefits
Time of Update: 2021-06-05
It is in line with the efficacy and safety of the two previous phase III clinical studies for patients with advanced prostate cancer with bone metastasis [1-2], and reached the expectations of the treatment team The goal, and the medication is safe and convenient.
-
After 40 years of sharpening the sword, what breakthroughs lie behind the conquering of the famous "unmade medicine" target?
Time of Update: 2021-06-05
The development of KRAS G12C covalent inhibitors However, the discovery of pockets that can bind to KRAS G12C mutants does not mean that the road to the development of KRAS targeted anti-cancer therapies is "unblocked.
-
Professor Fan Lei: First-line treatment of chronic lymphocytic leukemia|Jinling Lymphatic Tumor Forum 2021
Time of Update: 2021-06-05
Professor Fan Lei said that although immunochemotherapy has improved the overall prognosis of CLL patients, the prognosis of CLL patients with high risk [IGHV not mutated and/or del(11q) or del(17p)] after standard FCR treatment is still not optimistic.
-
Professor Fan Yaohua: Liver cancer with Chinese characteristics, multiple treatment methods
Time of Update: 2021-06-05
In addition, due to the poor status of secondary tumor prevention in my country, some patients with hepatitis B lack good antiviral treatment and follow-up, resulting in the first diagnosis of liver cancer at the advanced stage.
-
Wonderful review｜A series of activities of the Lymphocytic Disease Group of the Hematology Branch of the Chinese Medical Association-the 2nd Bethune's Lymphoma Youth Forum in 2021
Time of Update: 2021-06-05
Conference speech The first session of the academic lecture: Progress in the molecular pathology of highly aggressive B-cell lymphoma was presided over by Professor Zhou Xiaoge from Beijing Friendship Hospital and Professor Wang Yinping from Jilin University First Hospital.
-
2021 ASCO | A quick overview of the major research progress of the immunization session
Time of Update: 2021-06-05
This phase I/II study mainly evaluates the safety/tolerability and preliminary anti-tumor activity of HB-201 monotherapy and HB-201&HB-202 alternative therapy in 25 HPV16-positive cancer patients.
-
6 mutations are associated with increased risk of blood clots in cancer patients
Time of Update: 2021-06-05
The Khorana score combines cancer type, blood count before chemotherapy (including the use of erythropoietin stimulants), and body mass index to design a risk score; however, we still hope to be able to more accurately identify high-risk patients.
The clinical risk factors for CAT include cytotoxic chemotherapy (hazard ratio, 1.
-
Copanlisib combined with rituximab can significantly improve the prognosis of patients with recurrent iNHL
Time of Update: 2021-06-05
Based on this, Professor Matthew J Matasar and others conducted the CHRONOS-3 study, which is a multi-center, double-blind, randomized, placebo-controlled phase III clinical trial that evaluated Copanlisib combined with rituximab versus placebo Efficacy and safety of combined rituximab in patients with relapsed iNL.
